HealthEquity (NASDAQ:HQY) Price Target Raised to $129.00 at JPMorgan Chase & Co.

HealthEquity (NASDAQ:HQY) had its target price increased by JPMorgan Chase & Co. from $126.00 to $129.00 in a report released on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 32.56% from the stock’s current price.

HQY has been the topic of a number of other research reports. BTIG Research restated a “buy” rating and issued a $130.00 target price on shares of HealthEquity in a research report on Thursday. Barrington Research reiterated an “outperform” rating and issued a $125.00 price target on shares of HealthEquity in a research note on Friday, August 29th. Wall Street Zen lowered HealthEquity from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Jefferies Financial Group increased their target price on HealthEquity from $130.00 to $134.00 and gave the company a “buy” rating in a research report on Wednesday, September 3rd. Finally, Royal Bank Of Canada lifted their price target on HealthEquity from $109.00 to $110.00 and gave the company an “outperform” rating in a research note on Wednesday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $120.07.

HealthEquity Price Performance

Shares of HQY traded down $1.33 during midday trading on Thursday, hitting $97.31. The company’s stock had a trading volume of 780,954 shares, compared to its average volume of 994,533. The company has a quick ratio of 4.23, a current ratio of 4.23 and a debt-to-equity ratio of 0.47. HealthEquity has a one year low of $74.07 and a one year high of $116.65. The stock has a market capitalization of $8.38 billion, a price-to-earnings ratio of 59.13, a price-to-earnings-growth ratio of 1.47 and a beta of 0.18. The company’s fifty day simple moving average is $96.42 and its two-hundred day simple moving average is $96.88.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings data on Wednesday, December 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. The business had revenue of $322.16 million for the quarter, compared to analyst estimates of $320.92 million. HealthEquity had a return on equity of 12.04% and a net margin of 11.49%.HealthEquity’s revenue was up 7.2% compared to the same quarter last year. During the same period last year, the firm posted $0.78 earnings per share. HealthEquity has set its FY 2026 guidance at 3.870-3.950 EPS. As a group, equities analysts expect that HealthEquity will post 2.32 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Delano Ladd sold 1,500 shares of HealthEquity stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $104.56, for a total transaction of $156,840.00. Following the completion of the transaction, the executive vice president owned 75,479 shares of the company’s stock, valued at $7,892,084.24. This trade represents a 1.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Henry Fiore sold 1,781 shares of the business’s stock in a transaction that occurred on Tuesday, October 7th. The shares were sold at an average price of $88.21, for a total value of $157,102.01. Following the completion of the transaction, the executive vice president directly owned 49,795 shares in the company, valued at approximately $4,392,416.95. This trade represents a 3.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 10,781 shares of company stock valued at $1,016,707. Insiders own 1.50% of the company’s stock.

Institutional Trading of HealthEquity

Several hedge funds have recently bought and sold shares of HQY. Invesco Ltd. increased its position in shares of HealthEquity by 50.6% during the first quarter. Invesco Ltd. now owns 2,446,198 shares of the company’s stock worth $216,171,000 after acquiring an additional 821,425 shares in the last quarter. Norges Bank bought a new stake in HealthEquity during the 2nd quarter worth approximately $75,072,000. Westfield Capital Management Co. LP raised its stake in shares of HealthEquity by 124.6% in the second quarter. Westfield Capital Management Co. LP now owns 1,265,208 shares of the company’s stock worth $132,543,000 after purchasing an additional 701,819 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of HealthEquity by 148.5% in the second quarter. AQR Capital Management LLC now owns 1,107,448 shares of the company’s stock worth $116,016,000 after purchasing an additional 661,795 shares during the last quarter. Finally, Nuveen LLC bought a new position in shares of HealthEquity in the first quarter valued at approximately $53,076,000. Institutional investors and hedge funds own 99.55% of the company’s stock.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.